ChiCTR-TRC-12002072
正在进行
/
/
/
2012-04-04
/
/
women undergoing IVF-ET cycles
Ovarian response in poor ovarian responder: a randomized controlled trial on the effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles
Ovarian response in poor ovarian responder: a randomized controlled trial on the effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles
The effect of mid-follicular phase recombinant luteinizing hormone versus low dose urinary human chorionic gonadotrophin supplement on in-vitro fertilization cycles
随机平行对照
其它
RCT
Double-blind
Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong
/
60
/
1990-01-01
1990-01-01
/
1. History of 2 episodes of poor ovarian response (less than 3 mature follicles on ovulatory dose of hCG or less than 3 mature oocytes retrieved) despite maximal stimulation; or 2. Patients fulfill two out of three of the following features: I.Age >=40 or any other risk factors: (1)History of ovarian surgery; (2)History of salpingectomy; (3)History of chemotherapy; (4)Present of ovarian endometrioma.;
登录查看1. Body mass index more than 30kg/m2; 2. Absent of one ovary; 3. History of polycystic ovarian disease; 4. Present of uterine abnormalities; 5. Present of endocrine/metabolic/autoimmune disease; 6. Incompetence or refuse for informed consent.;
登录查看Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong
/
PDL1 三阴性乳腺癌 atezolizumab
BioArtMED2025-06-21
糖尿病 GLP-1/GIP
恒瑞医药2025-06-21
肥胖 Wegovy
一度医药2025-06-21
ADA 糖尿病
箕星药业科技2025-06-21
乙肝 乙肝疫苗
肝脏时间2025-06-21
药物临床试验
Insight数据库2025-06-21
B细胞恶性肿瘤 自身免疫性疾病 Capstan
博生吉细胞研究2025-06-21
结节性硬化症 三叉神经痛 BD项目
美柏资本2025-06-21
正大天晴药业集团2025-06-21